Literature DB >> 9215291

Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity.

B L Nyomba1, L Berard, L J Murphy.   

Abstract

The majority of insulin-like growth factor I (IGF-I) circulates in blood bound to a family of IGF-binding proteins (IGFBPs). Only a small fraction of IGF-I is unbound or free, and one of the postulated roles of the IGFBPs is regulation of this free component, thereby increasing IGF-I bioavailability. Whether free IGF-I plays a physiological role in glucose homeostasis, however, is not clear. In this study, we examined the effects of acute changes in serum insulin on free IGF-I, total IGF-I, IGFBP-1, and IGFBP-3 in 11 healthy subjects. Glucose (0.3 g/kg) and insulin (0.05 U/kg) were injected iv at 0 and 20 min, respectively. Blood samples were drawn at defined intervals for 3 h, and insulin sensitivity (SI) was computed by Bergman's minimal model. Serum insulin reached a first peak after glucose injection and a second, higher peak after exogenous insulin administration. Although the total IGF-I level remained constant for the duration of the experiment, free IGF-I decreased by 20% 20 min after the first insulin peak and by 35% 20 min after the second peak. IGFBP-1 first declined to 20% below basal, then rose to 3-fold the basal level. IGFBP-3 increased linearly to 20% above basal by the end of the experiment, and this increase mirrored the decline of free IGF-I. In the fasting state, free IGF-I was positively correlated with SI (r = 0.52; P < 0.005) and inversely correlated with glucose (r = -0.51; P < 0.005) and IGFBP-1 (r = -0.65; P < 0.001). In conclusion, free IGF-I is acutely regulated by insulin and correlates with SI, suggesting that it may play a physiological role in glucose homeostasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215291     DOI: 10.1210/jcem.82.7.4070

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Differences in the GH-IGF-I axis in children of different weight and fitness status.

Authors:  Peter A Hosick; Robert G McMurray; A C Hackney; Claudio L Battaglini; Terry P Combs; Joanne S Harrell
Journal:  Growth Horm IGF Res       Date:  2012-03-20       Impact factor: 2.372

2.  Associations between genetic polymorphisms of insulin-like growth factor axis genes and risk for age-related macular degeneration.

Authors:  Chung-Jung Chiu; Yvette P Conley; Michael B Gorin; Gary Gensler; Chao-Qiang Lai; Fu Shang; Allen Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-25       Impact factor: 4.799

Review 3.  Insulin-Like growth factor I: implications in aging.

Authors:  E Arvat; F Broglio; E Ghigo
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

4.  Multipathway modulation of exercise and glucose stress effects upon GH secretion in healthy men.

Authors:  Johannes D Veldhuis; Thomas P Olson; Paul Y Takahashi; John M Miles; Michael J Joyner; Rebecca J Yang; Jean Wigham
Journal:  Metabolism       Date:  2015-05-15       Impact factor: 8.694

Review 5.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

6.  Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.

Authors:  Brenda M Birmann; Marian L Neuhouser; Bernard Rosner; Demetrius Albanes; Julie E Buring; Graham G Giles; Qing Lan; I-Min Lee; Mark P Purdue; Nathaniel Rothman; Gianluca Severi; Jian-Min Yuan; Kenneth C Anderson; Michael Pollak; Nader Rifai; Patricia Hartge; Ola Landgren; Lawrence Lessin; Jarmo Virtamo; Robert B Wallace; JoAnn E Manson; Graham A Colditz
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

7.  Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Elizabeth A Platz; Cathee Till; Catherine M Tangen; Phyllis J Goodman; Alan Kristal; Howard L Parnes; Yuzhen Tao; William D Figg; M Scott Lucia; Ashraful Hoque; Ann W Hsing; Ian M Thompson; Michael Pollak
Journal:  Cancer Prev Res (Phila)       Date:  2013-01-11

Review 8.  Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.

Authors:  Silvia Giovannini; Emanuele Marzetti; Stephen E Borst; Christiaan Leeuwenburgh
Journal:  Mech Ageing Dev       Date:  2008-08-13       Impact factor: 5.432

9.  Acute hormonal responses of a high impact physical exercise session in early postmenopausal women.

Authors:  W Kemmler; L Wildt; K Engelke; R Pintag; M Pavel; B Bracher; J Weineck; W Kalender
Journal:  Eur J Appl Physiol       Date:  2003-07-09       Impact factor: 3.078

10.  Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.

Authors:  Sarah M Rudman; Kathryn P Gray; Julie L Batista; Michael J Pitt; Edward L Giovannucci; Peter G Harper; Massimo Loda; Lorelei A Mucci; Christopher J Sweeney
Journal:  BJU Int       Date:  2016-03-08       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.